49
Participants
Start Date
April 30, 2010
Primary Completion Date
October 31, 2011
Study Completion Date
October 31, 2011
Ziprasidone
The minimum dose during study participation will be 40 mg/day, and the maximum dose allowed will be 160 mg/day.
Placebo
Inactive control
University of South Florida Institute for Research in Psychiatry, Tampa
Lindner Center of Hope University of Cincinnati Medical Center, Mason
VA Palo Alto Health Care System & Stanford School of Medicine, Palo Alto
Collaborators (1)
Pfizer
INDUSTRY
University of South Florida
OTHER
Lindner Center of HOPE
OTHER
VA Palo Alto Health Care System
FED